nemtabrutinib
Sponsor Merck & CO INC. · listed as MRK
nemtabrutinib is a drug asset sponsored by Merck & CO INC., listed as MRK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected May 19, 2027 (day precision, medium confidence), tied to trial NCT05624554. That trial is in Phase 3 and currently active not recruiting, studying Chronic Lymphocytic Leukemia. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for nemtabrutinib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05624554 catalyst | Phase 3 | Active, not recruiting | 2027-05-19 | Experimental | Merck Sharp & Dohme LLC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
| NCT05947851 | Phase 3 | Recruiting | 2032-06-01 | Experimental | Merck Sharp & Dohme LLC | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma… |
| NCT06136559 | Phase 3 | Recruiting | 2032-09-07 | Experimental | Merck Sharp & Dohme LLC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More MRK catalysts